Skip to content
EntityQ4462924· pop 9· linked from 183 articles

riamilovir

Sign in to save

Also known as triazavirin

Riamilovir, sold under the brand name Triazavirin, is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs.

~2 min read

Encyclopedic overview

4 sections
Contents
  • Medical uses
  • Research
  • See also
  • References

Riamilovir, sold under the brand name Triazavirin, is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs.

The principal action of riamilovir is to inhibit the synthesis of viral ribonucleic acid (RNA) and the replication of viral genomic fragments through its synthetic analogue to the bases of purine nucleosides.

Excerpted from Wikipedia’s “riamilovir” article, available under the CC BY-SA 4.0 licence.